Literature DB >> 19718697

An algorithm to identify incident myocardial infarction using Medicaid data.

Neesha N Choma1, Marie R Griffin, Robert L Huang, Edward F Mitchel, Lisa A Kaltenbach, Patricia Gideon, Shannon M Stratton, Christianne L Roumie.   

Abstract

PURPOSE: Studies of non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular events using administrative data require identification of incident acute myocardial infarctions (AMIs) and information on whether confounders differ by NSAID status.
METHODS: We identified patients with a first AMI hospitalization from Tennessee Medicaid files as those with primary ICD-9 discharge diagnosis 410.x and hospitalization stay of > 2 calendar days. Eligible persons were non-institutionalized, aged 50-84 years between 1999-2004, had continuous enrollment and no AMI, stroke, or non-cardiovascular serious medical illness in the prior year. Of 5524 patients with a potential first AMI, a systematic sample (n = 350) was selected for review. Using defined criteria, we classified events using chest pain history, EKG, and cardiac enzymes, and calculated the positive predictive value (PPV) for definite or probable AMI.
RESULTS: 337 of 350 (96.3%) charts were abstracted and 307 (91.1%), 6 (1.8%), and 24 (7.1%) events were categorized as definite, probable, and no AMI, respectively. PPV for any definite or probable AMI was 92.8% (95% CI 89.6-95.2); for an AMI without an event in the past year 91.7% (95% CI 88.3-94.2), and for an incident AMI was 72.7% (95% CI 67.7-77.2). Age-adjusted prevalence of current smoking (46.4% vs. 39.1%, p = 0.35) and aspirin use (36.9% vs. 35.9%, p = 0.90) was similar among NSAID users and non-users
CONCLUSIONS: ICD-9 code 410.x had high predictive value for identifying AMI. Among those with AMI, smoking and aspirin use was similar in NSAID exposure groups, suggesting these factors will not confound the relationship between NSAIDs and cardiovascular outcomes. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718697     DOI: 10.1002/pds.1821

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  24 in total

1.  Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Niteesh Choudhry; Jun Liu; Robert J Glynn; Daniel H Solomon
Journal:  Am J Med       Date:  2015-02-03       Impact factor: 4.965

2.  PheValuator: Development and evaluation of a phenotype algorithm evaluator.

Authors:  Joel N Swerdel; George Hripcsak; Patrick B Ryan
Journal:  J Biomed Inform       Date:  2019-07-29       Impact factor: 6.317

3.  Position matters: Validation of medicare hospital claims for myocardial infarction against medical record review in the atherosclerosis risk in communities study.

Authors:  Montika Bush; Til Stürmer; Sally C Stearns; Ross J Simpson; M Alan Brookhart; Wayne Rosamond; Anna M Kucharska-Newton
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-06       Impact factor: 2.890

4.  Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.

Authors:  Nam-Kyong Choi; Daniel H Solomon; Theodore N Tsacogianis; Joan E Landon; Hong Ji Song; Seoyoung C Kim
Journal:  J Bone Miner Res       Date:  2017-02-07       Impact factor: 6.741

5.  Design for validation of acute myocardial infarction cases in Mini-Sentinel.

Authors:  Sarah L Cutrona; Sengwee Toh; Aarthi Iyer; Sarah Foy; Elizabeth Cavagnaro; Susan Forrow; Judith A Racoosin; Robert Goldberg; Jerry H Gurwitz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

6.  Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.

Authors:  Seoyoung C Kim; Robert J Glynn; Jun Liu; Brendan M Everett; Allison B Goldfine
Journal:  Acta Diabetol       Date:  2014-10-14       Impact factor: 4.280

7.  Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.

Authors:  Daniel H Solomon; Jeffrey R Curtis; Kenneth G Saag; Joyce Lii; Lang Chen; Leslie R Harrold; Lisa J Herrinton; David J Graham; Mary K Kowal; Bindee Kuriya; Liyan Liu; Marie R Griffin; James D Lewis; Jeremy A Rassen
Journal:  Am J Med       Date:  2013-08       Impact factor: 4.965

8.  Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program.

Authors:  Sarah L Cutrona; Sengwee Toh; Aarthi Iyer; Sarah Foy; Gregory W Daniel; Vinit P Nair; Daniel Ng; Melissa G Butler; Denise Boudreau; Susan Forrow; Robert Goldberg; Joel Gore; David McManus; Judith A Racoosin; Jerry H Gurwitz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-06-29       Impact factor: 2.890

9.  Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization.

Authors:  Kurt Niesner; Harvey J Murff; Marie R Griffin; Brian Wasserman; Robert Greevy; Carlos G Grijalva; Christianne L Roumie
Journal:  Epidemiology       Date:  2013-03       Impact factor: 4.822

10.  Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort.

Authors:  Emily S Brouwer; Sonia Napravnik; Joseph J Eron; Ross J Simpson; M Alan Brookhart; Brant Stalzer; Michael Vinikoor; Michelle Floris-Moore; Til Stürmer
Journal:  Med Care       Date:  2015-06       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.